however, no direct head-to-head trials comparing retatrutide with licensed agents have been completed, and any comparative efficacy conclusions remain hypothesis-generating at this stage
And hopefully then we are not looking our age
Clinical data shows that the higher 7.2mg dose (Wegovy HD) is highly effective, particularly for patients who have stopped losing weight on the standard 2.4mg dose
These methods are validated and quality-controlled
Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH. Survodutides GLP1 agonism decreases appetite while increasing fullness and satiety, 10 while its glucagon agonism is thought to directly act on the liver to reduce hepatic fat, regulate metabolic function, resolve inflammation, and improve fibrosis
Monitoring for gastrointestinal symptoms becomes particularly important when initiating Wegovy in patients already taking PPIs